Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)-Reference-Cited by-同舟云学术

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

Published:2014-04-10 Issue:6 Volume:92 Page:527-536
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Angelucci Emanuele¹,Santini Valeria²,Di Tucci Anna Angela¹,Quaresmini Giulia³,Finelli Carlo⁴,Volpe Antonio⁵,Quarta Giovanni⁶,Rivellini Flavia⁷,Sanpaolo Grazia⁸,Cilloni Daniela⁹,Salvi Flavia¹⁰,Caocci Giovanni¹¹,Molteni Alfredo¹²,Vallisa Daniele¹³,Voso Maria Teresa¹⁴,Fenu Susanna¹⁵,Borin Lorenza¹⁶,Latte Giancarlo¹⁷,Alimena Giuliana¹⁸,Storti Sergio¹⁹,Piciocchi Alfonso²⁰,Fazi Paola²⁰,Vignetti Marco²⁰,Tura Sante²¹

Affiliation:

1. Hematology and Bone Marrow Transplantation Unit; Ospedale Oncologico di Riferimento Regionale “Armando Businco”; Cagliari Italy

2. Division of Hematology; University of Florence; Florence Italy

3. Hematology and Bone Marrow Transplant Unit; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy

4. Division of Hematology; Policlinico S. Orsola-Malpighi; Bologna Italy

5. Division of Hematology; San Giuseppe Moscati Hospital; Avellino Italy

6. Division of Hematology; Ospedale A. Perrino; Brindisi Italy

7. UO Medicina Interna e Onco-Ematologica P.O. “Umberto I”; Nocera Inferiore Italy

8. Division of Hematology; IRCCS “Casa Sollievo della Sofferenza”; San Giovanni Rotondo Italy

9. Department of Clinical and Biological Sciences; University of Turin; Turin Italy

10. Division of Hematology; A.O. Nazionale Santi Antonio e Biagio e C. Arrigo; Alessandria Italy

11. Bone Marrow Transplantation Center; R. Binaghi Hospital; Cagliari Italy

12. Division of Hematology; Niguarda Ca’ Granda Hospital; Milan Italy

13. Division of Medical Oncology and Hematology; Hospital of Piacenza; Piacenza Italy

14. Division of Hematology; Università Cattolica del Sacro Cuore; Rome Italy

15. Division of Hematology; San Giovanni Hospital; Rome Italy

16. Division of Hematology; Monza Italy

17. Division of Hematology; S. Francesco Hospital; Nuoro Italy

18. Division of Hematology; “Sapienza”University of Rome; Rome Italy

19. Division of Hematology and Medical Oncology; Campobasso University; Campobasso Italy

20. GIMEMA Data Center; GIMEMA Foundation; Rome Italy

21. University of Bologna; Bologna Italy

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12300/fullpdf

Reference46 articles.

1. Iron overload in MDS-pathophysiology, diagnosis, and complications;Gattermann;Ann Hematol,2011

2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload;Nolte;Ann Hematol,2013

3. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome;List;J Clin Oncol,2012

4. Deferasirox treatment of iron-overloaded chelation-naive and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange;Gattermann;Eur J Haematol,2012

5. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes;Greenberg;Leuk Res,2010

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curcumin regulates autophagy through SIRT3-SOD2-ROS signaling pathway to improve quadriceps femoris muscle atrophy in KOA rat model;Scientific Reports;2024-04-08

2. Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR;Journal of Clinical Medicine;2023-10-17

3. Supportive Care for Patients With Myelodysplastic Syndromes;The Cancer Journal;2023-05

4. Comparative characteristics of humoral immunity indicators and their relationship with chelation therapy in thalassemia;Meditsinskiy sovet = Medical Council;2022-11-16

5. 鉄過剰症の病態と治療;Nihon Naika Gakkai Zasshi;2022-11-10